SPHR.Y Stock Overview
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Starpharma Holdings Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | AU$0.82 |
52 Week High | AU$3.45 |
52 Week Low | AU$0.77 |
Beta | 0.82 |
1 Month Change | -6.79% |
3 Month Change | -34.08% |
1 Year Change | -74.29% |
3 Year Change | -94.66% |
5 Year Change | -89.46% |
Change since IPO | -87.01% |
Recent News & Updates
Recent updates
Shareholder Returns
SPHR.Y | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | -3.5% | 2.2% | 0.2% |
1Y | -74.3% | 25.5% | 28.1% |
Return vs Industry: SPHR.Y underperformed the US Pharmaceuticals industry which returned 25.8% over the past year.
Return vs Market: SPHR.Y underperformed the US Market which returned 28.8% over the past year.
Price Volatility
SPHR.Y volatility | |
---|---|
SPHR.Y Average Weekly Movement | 10.0% |
Pharmaceuticals Industry Average Movement | 9.7% |
Market Average Movement | 6.1% |
10% most volatile stocks in US Market | 16.8% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SPHR.Y's share price has been volatile over the past 3 months.
Volatility Over Time: SPHR.Y's weekly volatility has decreased from 18% to 10% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1997 | 45 | Cheryl Maley | https://starpharma.com |
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom. It is also involved in the development of DEP cabazitaxel that is in Phase 2 clinical trial for the treatment of prostate and other cancers, DEP docetaxel that is in Phase 2 clinical trials for the treatment of colorectal and other cancers, DEP irinotecan that is in Phase 2 clinical trials f for the treatment of pancreatic and other cancers; and EP gemcitabine, DEP HER-2 ADC, and DEP HER-2 radiotherapy completed preclinical trials for the treatment of solid cancers.
Starpharma Holdings Limited Fundamentals Summary
SPHR.Y fundamental statistics | |
---|---|
Market cap | US$33.56m |
Earnings (TTM) | -US$5.47m |
Revenue (TTM) | US$6.86m |
4.9x
P/S Ratio-6.1x
P/E RatioIs SPHR.Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
SPHR.Y income statement (TTM) | |
---|---|
Revenue | AU$10.52m |
Cost of Revenue | AU$11.68m |
Gross Profit | -AU$1.16m |
Other Expenses | AU$7.24m |
Earnings | -AU$8.39m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.02 |
Gross Margin | -11.02% |
Net Profit Margin | -79.79% |
Debt/Equity Ratio | 0% |
How did SPHR.Y perform over the long term?
See historical performance and comparison